How One Family’s Fundraising Drive Revolutionized Gene Therapy for Rare Disease

When Eliza O’Neill was a toddler in South Carolina, she loved parading around the house in her mother’s high heels, accessorizing with hats and scarves. However, by the time she turned 3 years old, her parents began noticing troubling developmental delays. Consequently, what started as concerns about speech development would soon lead to a devastating diagnosis that would reshape their lives-and ultimately, the landscape of rare disease research.

Cara O’Neill, a pediatrician, initially thought her daughter had a pragmatic speech delay. Eliza had learned many words but wasn’t using them appropriately in social situations. In 2013, a colleague suggested testing for metabolic disorders, simply to rule them out.

The test came back positive for Sanfilippo syndrome, a rare inherited disease Cara had studied briefly in medical school. “When they said the word, it all kind of came rushing back,” she recalls. “And it was just this bale of dread, like, oh, my goodness, this is horrific.”

Understanding the Devastating Diagnosis

Children diagnosed with Sanfilippo syndrome carry a faulty gene that prevents their bodies from breaking down heparin sulfate, a molecule critical to normal cell function. As this substance accumulates in the body, it triggers severe and progressive complications. Furthermore, the prognosis is particularly grim-affected children gradually lose their ability to speak and walk, experience seizures, and typically don’t live past their teens, according to the Cure Sanfilippo Foundation.

For Glenn O’Neill, Eliza’s father, the full weight of the diagnosis took time to register. “It wasn’t really until I got home that I realized how quickly the degeneration happened,” he says. “And that was really the point where we said, ‘Gosh. Whatever we need to do, we need to do it now.'”

The O’Neill family faced an impossible timeline. Their daughter’s condition would deteriorate rapidly, and traditional research funding cycles move notoriously slowly. Consequently, they made a decision that would prove transformative not just for their family, but for the entire field of rare disease research.

A Researcher’s Decades-Long Quest

Meanwhile, at Nationwide Children’s Hospital in Columbus, Ohio, researcher Haiyan Fu had been working on a potential solution since the late 1990s. Her experimental gene therapy used a modified virus to deliver a working copy of the broken gene directly to patients’ cells-a cutting-edge approach that showed remarkable promise in mouse models.

“And if we treat early, it could be potentially a cure,” Fu says. “So I can’t give up.”

Nevertheless, maintaining the research program proved extraordinarily challenging. Funding for rare disease research is notoriously difficult to secure, as pharmaceutical companies typically focus on conditions affecting larger patient populations. In addition, traditional grant cycles can take years to process, and there’s no guarantee of approval. By 2009, Fu thought she might have to abandon the project entirely due to lack of financial support.

When Families and Researchers Unite

The O’Neill family’s determination intersected with Fu’s research at a critical juncture. Facing the possibility that promising research might shut down just as their daughter needed it most, the family took unprecedented action. They established the Cure Sanfilippo Foundation, channeling their medical knowledge, business acumen, and parental desperation into a focused fundraising effort.

This family-driven funding model represented a paradigm shift in rare disease research. Rather than waiting for traditional institutional grants, the foundation could direct resources quickly and strategically to the most promising research. Moreover, the O’Neills brought a sense of urgency that resonated with donors and researchers alike.

The collaboration between the O’Neill family and Fu’s research team exemplifies a growing trend in medical research. Patient advocacy groups and affected families are increasingly becoming essential partners in advancing treatments for rare diseases. In fact, this model has proven particularly effective for conditions affecting small patient populations that might otherwise be overlooked by major pharmaceutical companies.

Broader Implications for Rare Disease Research

The O’Neill family’s approach to funding gene therapy research has created ripples throughout the rare disease community. Their foundation continues to support critical work, demonstrating that family-led fundraising can bridge the gap between promising laboratory discoveries and actual treatments. Furthermore, their model has inspired other families facing similar diagnoses to take active roles in advancing research.

Gene therapy itself represents one of the most promising frontiers in medicine. By correcting genetic defects at their source, these treatments offer hope for conditions that were previously considered untreatable. However, developing these therapies requires substantial investment and years of meticulous research-resources that are often unavailable for rare diseases affecting fewer than 200,000 people in the United States.

The intersection of parental advocacy and scientific innovation demonstrates how urgent need can accelerate medical progress. When families like the O’Neills provide both funding and motivation, researchers can maintain momentum through the inevitable setbacks and challenges of experimental therapy development. Consequently, treatments that might have languished in early-stage research can advance toward human trials and eventual clinical application.

A Legacy Beyond One Family

The O’Neills’ journey from a devastating diagnosis to becoming leaders in rare disease research advocacy illustrates both the challenges and possibilities of modern medical research. Their experience underscores a fundamental truth: breakthrough treatments often require more than just scientific expertise-they need passionate advocates willing to fight for funding and attention.

While Eliza’s story catalyzed this particular research effort, the ultimate impact extends far beyond a single patient or family. The gene therapy research that the O’Neills helped sustain could potentially benefit hundreds or thousands of children diagnosed with Sanfilippo syndrome in the future. Moreover, advances in gene therapy for this condition may inform treatment approaches for other rare genetic disorders.

The collaboration between desperate parents and dedicated researchers reveals how medical progress sometimes requires unconventional funding models and unprecedented urgency. In the face of a diagnosis that typically allows less than a decade of life, the O’Neill family refused to accept that promising research might simply fade away due to lack of resources. Instead, they created a foundation that continues to drive critical research forward, transforming both scientific possibility and patient outcomes.